New Dengue Vaccine Pricing Disclosed

Qdenga vaccine pricing depends on country and market segment
Dengue vaccine price 2023
by Gerd Altmann
Tokyo (Precision Vaccinations News)

As the new tetravalent dengue fever vaccine from Takeda Pharmaceutical Company rapidly gains approvals around the globe, many interested parties were asking what this innovative disease protection would cost.

'We aim to make QDENGA® available to all eligible for vaccination in the countries where approved,' stated Takeda's presentation led by Ramona Sequeira, President, Global Portfolio Division, on March 15, 2023.

For example, Takeda disclosed these classifications:

  • PRIVATE ENDEMIC - Maximum retail price for Indonesia is USD 40 per dose, USD 26 ex-factory.
  • PUBLIC ENDEMIC - The Company aims to price lower than average for innovative vaccines with one pricing corridor and a discount matrix.
  • TRAVEL - Pricing will resemble other innovative travel vaccines in their respective countries. The retail price in Germany is USD 115 per dose, USD 80 ex-factory.

Takeda stated that implementing QDENGA can potentially create significant cost savings for individuals and governments, considering economic factors such as cost of care, missed work, lost tourism, etc.

As of March 27, 2023, QDENGA is authorized in Indonesia, the European Union, the U.K., and Brazil.

Target launches in >20 countries by 2025, representing 55% of the eligible at-risk population.

Previously, on November 22, 2022, the U.S. Food and Drug Administration accepted and granted priority review of QDENGA's Biologics License Application for preventing dengue disease caused by any of the four dengue virus serotypes in individuals four years through 60 years.

The Pan American Health Organization and the World Health Organization have issued various dengue travel alerts regarding outbreaks as of March 27, 2023. More than 4 billion people are at risk per year.

During the summer of 2022, the Florida Department of Health in Miami-Dade County was under a mosquito-borne illness advisory regarding dengue (DENV-3) locally-acquired and international travel-related cases.

However, the U.S. CDC has not issued a travel advisory for south Florida's ongoing dengue reports.

Our Trust Standards: Medical Advisory Committee

Article by
Donald Hackett